Menu
Back to User profile » Professor Afisi Ismaila
Papers published by Professor Afisi Ismaila:
Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany
Beeh KM, Rothnie KJ, Claussen J, Hardtstock F, Knapp RK, Wilke T, Czira A, Compton C, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:945-956
Published Date: 17 April 2024
Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study
Czira A, Akiyama S, Ishii T, Wood RP, Camidge LJ, Wallis H, Jennison T, Wild RAC, Yarita M, Hashimoto K, Rothnie KJ, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2933-2953
Published Date: 8 December 2023
Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK
Rothnie KJ, Numbere B, Gelwicks S, Lu Y, Sharma R, Compton C, Ismaila AS, Quint JK
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2673-2685
Published Date: 21 November 2023
Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo C, Yeap J, Wild R, Compton C, Rothnie KJ, Herth FJ, Quint JK, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2039-2054
Published Date: 15 September 2023
Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
Kendall R, Martin AA, Shah D, Shukla S, Compton C, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1815-1825
Published Date: 21 August 2023
Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1431-1444
Published Date: 13 July 2023
Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review
Czira A, Purushotham S, Iheanacho I, Rothnie KJ, Compton C, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:719-731
Published Date: 29 April 2023
Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:643-659
Published Date: 19 April 2023
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA
Hanania NA, Bunner SH, Bengtson LGS, Ismaila AS, Bogart M
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:407-418
Published Date: 24 March 2023
Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:231-245
Published Date: 5 March 2023
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
Paly VF, Vallejo-Aparicio LA, Martin A, Izquierdo JL, Riesco JA, Soler-Cataluña JJ, Abreu C, Biswas C, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:3097-3109
Published Date: 16 December 2022
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
Halpin DM, Kendall R, Shukla S, Martin A, Shah D, Midwinter D, Beeh KM, Kocks JWH, Jones PW, Compton C, Risebrough NA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2745-2755
Published Date: 25 October 2022
Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting
Halpin DM, Rothnie KJ, Banks V, Czira A, Compton C, Wood R, Tritton T, Massey O, Wild R, Snowise N, Nikitin K, Sharma R, Ismaila AS, Vogelmeier CF
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2417-2429
Published Date: 24 September 2022
Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
Neches García V, Vallejo-Aparicio LA, Ismaila AS, Sicras-Mainar A, Sicras-Navarro A, González C, Cuervo R, Shukla S, García-Peñuela M
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2161-2174
Published Date: 7 September 2022
Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England
Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Duarte M, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1781-1795
Published Date: 10 August 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, Martinez FJ, Criner GJ, Martin N, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1633-1642
Published Date: 25 July 2022
Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
Rothnie KJ, Joksaite S, Sansbury LB, Compton C, Di Boscio V, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1455-1466
Published Date: 22 June 2022
Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
Mannino D, Bogart M, Germain G, Huang SP, Ismaila AS, Laliberté F, Jung Y, MacKnight SD, Stiegler MA, Duh MS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:491-504
Published Date: 5 March 2022
Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England
Sansbury LB, Lipson DA, Bains C, Anley GA, Rothnie KJ, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:415-426
Published Date: 3 March 2022
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
Shukla S, Shah D, Martin A, Risebrough NA, Kendall R, Vogelmeier CF, Boucot I, Tombs L, Bjermer L, Jones PW, Kerwin E, Compton C, Maltais F, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:3105-3118
Published Date: 13 November 2021
Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England
Sansbury LB, Wood RP, Anley GA, Nam Y, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2795-2808
Published Date: 8 October 2021
Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England
Sansbury LB, Rothnie KJ, Bains C, Compton C, Anley G, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2591-2604
Published Date: 15 September 2021
Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice
Sansbury LB, Bains C, Lipson DA, Ismaila AS, Landis SH
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1255-1264
Published Date: 6 May 2021
Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective
Schroeder M, Benjamin N, Atienza L, Biswas C, Martin A, Whalen JD, Izquierdo Alonso JL, Riesco Miranda JA, Soler-Cataluña JJ, Huerta A, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1621-1632
Published Date: 10 July 2020
Evaluating Patient Preferences of Maintenance Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Discrete Choice Experiment in the UK, USA and Germany
Lewis HB, Schroeder M, Gunsoy NB, Janssen EM, Llewellyn S, Doll HA, Jones PW, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:595-604
Published Date: 18 March 2020
Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review
Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:439-460
Published Date: 26 February 2020
Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review
Zhang S, King D, Rosen VM, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:417-438
Published Date: 26 February 2020
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
Ismaila AS, Risebrough N, Schroeder M, Shah D, Martin A, Goodall EC, Ndirangu K, Criner G, Dransfield M, Halpin DMG, Han MK, Lomas DA
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2681-2695
Published Date: 29 November 2019
Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
Sicras Mainar A, Huerta A, Navarro Artieda R, Monsó E, Landis SH, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2121-2129
Published Date: 12 September 2019
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study
Paly VF, Naya I, Gunsoy NB, Driessen MT, Risebrough N, Briggs A, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:939-951
Published Date: 3 May 2019
COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners
Meeraus W, Wood R, Jakubanis R, Holbrook T, Bizouard G, Despres J, Correia Da Silva C, Nachbaur G, Landis SH, Punekar Y, Aguilaniu B, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:51-63
Published Date: 18 December 2018
Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis
Ismaila AS, Huisman EL, Punekar YS, Karabis A
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2495-2517
Published Date: 16 November 2015
Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis
Huisman EL, Cockle SM, Ismaila AS, Karabis A, Punekar YS
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1863-1881
Published Date: 9 September 2015